Moxifloxacin Stulln

Moxifloxacin, the active ingredient in Moxifloxacin Stulln, is a fluoroquinolone presented as a topical ophthalmic solution for ocular use. It is employed to treat bacterial infections of the eye, such as conjunctivitis, keratitis and corneal ulcers, in adult patients. GNH USA supplies Moxifloxacin Stulln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a fluoroquinolone antibacterial used in ophthalmology to manage bacterial infections of the eye. - Bacterial conjunctivitis: reduces bacterial load and accelerates symptom resolution. - Bacterial keratitis: eradicates causative organisms and promotes corneal healing. - Corneal ulcer: prevents progression of infection and supports tissue repair.

Adverse reactions are primarily local ocular events, with occasional systemic manifestations.

Common Side Effects: - Stinging or burning sensation upon instillation. - Redness of the conjunctiva. - Transient blurred vision. - Foreign body sensation. - Mild eyelid edema.

Serious or Rare Side Effects: - Corneal epithelial toxicity. - Allergic contact dermatitis of the peri‑ocular skin. - Severe ocular inflammation. - Vision loss due to secondary infection. - Systemic hypersensitivity reactions.

Moxifloxacin should be used with awareness of specific safety considerations. - Pregnancy: Use only if the potential benefit outweighs the unknown risk. - Breastfeeding: Caution advised; limited data on excretion in milk. - Contact lenses: Remove lenses before administration and re‑insert after the solution has dried. - Pre‑existing ocular surface disease: Monitor closely for irritation. - Storage: Store at room temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Moxifloxacin may interact with other ophthalmic agents and systemic medications.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolone eye drops: increased risk of toxicity. - Use with topical corticosteroids without monitoring: may mask infection signs.

Moderate Interactions (Monitor Closely): - Systemic quinolones: additive QT‑prolongation risk. - Anticholinergic eye drops: potential for reduced drug absorption. - Non‑steroidal anti‑inflammatory eye drops: may increase local irritation. - Herbal supplements containing quinine: possible pharmacodynamic synergy.